European Society for Medical Oncology Congress

The latest news from ESMO, including researcher interviews and physician perspective.


Meeting NewsPerspective

Nivolumab with, without ipilimumab benefits patients with malignant pleural mesothelioma

September 10, 2017
MADRID — Nivolumab alone or in combination with ipilimumab as second- or third-line treatment demonstrated encouraging activity in patients…
Meeting NewsPerspective

Abemaciclib plus endocrine therapy improves outcomes for certain women with advanced breast cancer

September 10, 2017
MADRID — The addition of abemaciclib to endocrine therapy extended PFS and improved response rates among postmenopausal women with hormone…
Meeting NewsPerspective

Addition of ramucirumab to docetaxel extends PFS in advanced urothelial cancer

September 10, 2017
MADRID — The addition of ramucirumab to docetaxel conferred a small but statistically significant PFS benefit for patients with advanced or…
Meeting News

Annual CT scan does not offer survival benefit for completely resected NSCLC

September 9, 2017
MADRID — CT scan-based follow-up provided no significant survival benefit for patients who underwent complete resection for non-small cell lung…
Meeting NewsPerspective

Adjuvant imatinib beneficial for high-risk gastrointestinal stromal tumors

September 9, 2017
MADRID — Adjuvant treatment with imatinib improved outcomes among patients with high-risk gastrointestinal stromal tumors, according to final…
Meeting News

Addition of durvalumab to nab-paclitaxel may benefit patients with lung cancer

September 9, 2017
MADRID — The addition of durvalumab to nab-paclitaxel slightly improved PFS and also improved response rates among patients with nonsquamous…
Meeting News

Addition of pembrolizumab to chemotherapy improves outcomes in advanced NSCLC

September 9, 2017
MADRID — The addition of pembrolizumab to pemetrexed and carboplatin for first-line therapy extended survival and improved response rates among…
Meeting NewsPerspective

Osimertinib extends PFS in EGFR-positive lung cancer

September 9, 2017
MADRID — First-line osimertinib prolonged PFS by 54% compared with standard therapy among patients with EGFR-positive advanced non-small cell…
Meeting News

Pembrolizumab may become standard for advanced gastric cancer

September 8, 2017
MADRID — Pembrolizumab demonstrated promising activity in patients with pretreated recurrent or metastatic gastric or gastroesophageal junction…
Meeting News

Abiraterone acetate plus prednisone improves health-related quality of life in metastatic prostate cancer

September 8, 2017
MADRID — The addition of abiraterone acetate plus prednisone to androgen deprivation therapy improved health-related quality of life among men…